Omapatrilat- the story of Overture and Octave
- 1 November 2002
- journal article
- editorial
- Published by Elsevier in International Journal of Cardiology
- Vol. 86 (1) , 1-4
- https://doi.org/10.1016/s0167-5273(02)00389-3
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the ratJournal of the American College of Cardiology, 2002
- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololPublished by Elsevier ,2002
- Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololThe Lancet, 2002
- Omapatrilat Versus LisinoprilHypertension, 2001
- The underreporting of results and possible mechanisms of ‘negative’ drug trials in patients with chronic heart failureInternational Journal of Cardiology, 2001
- Consumer involvement in cardiovascular research: ways to combat bias and secrecyInternational Journal of Cardiology, 2000
- Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trialThe Lancet, 2000
- Omapatrilat — the ups and downs of an exciting but complicated new drugInternational Journal of Cardiology, 2000
- Heart failure 99 — the Moxcon storyInternational Journal of Cardiology, 1999
- OmapatrilatDrugs in R&D, 1999